Unilever Plc's USD 5.4 billion bid for a 23 percent stake in Hindustan Unilever is the largest Asia Pacific cross border inbound merger and acquisition (M&A) deal so far this year and is the fifth largest India Inbound M&A transaction on record till date.
Reliance Industries has bought back shares worth over Rs. 3,800 crore from public shareholders since the launch of its share repurchase programme in February -- achieving 37 per cent of the target with less than a month left for its completion.
Manoj Murlidharan Vayalar, IIFL is of the view that Piramal Healthcare can go upto Rs 502, keeping a stop loss at Rs 482. Punjab National Bank can touch Rs 702 and Sun Pharma has target of Rs 686.
Manoj Murlidharan Vayalar, Associate Vice President-Derivatives at IIFL PReMIA is of the view that, Piramal Healthcare is expected to go upto Rs 490, so one can keep a stop loss of Rs 465.
It was a range bound session for the market as the Nifty perked up a bit in late trade to close around 5270. It is still trapped in a 50 point trading range, said Udayan Mukherjee, managing editor of CNBC-TV18.
Piramal Healthcare is looking to acquire contract research and manufacturing business of Ind-Swift facilities for Rs 1000 crore, reports Business Standard.
Piramal Healthcare's consolidated net profit fell significantly to Rs 4 crore in the quarter ended June 2012 as against Rs 89 crore in a year ago period due to sharp spike in finance cost and exceptional expenses.
Paints, Cement, Pharma and Textile sectors will be getting astrological support, says Satish Gupta of http://astrostocktips.in
Personal care, Leather, Pharma, Paints & Varnish sectors will be getting astrological support, says Satish Gupta of http://astrostocktips.in
After a long wait, Ipca Laboratories has finally received approval for its Indore facility from the US FDA. This facility along with its Silvassa facility would be now used to manufacture drugs to the US market.
Pharma major Piramal Healthcare is set to be renamed as Piramal Enterprises following its entry into diversified business activities in the recent past. The rechristening comes four years after Nicholas Piramal became Piramal Healthcare.
Led by Piramal Healthcare, foreign investments by Indian companies in June rose by 50.21% from the previous month to USD 3.53 billion despite a slowdown in the global economy.
Piramal Healthcare in its board meeting held on May 03 has recommended dividend of Rs 17.5 per equity share of face value of Rs 2 (i.e. at 875%) for the financial year ended March 31, 2012.
The value of merger & acquisition (M&As) deals in the country during the second quarter of this year plunged 72% to USD 3 billion over the first quarter, impacted by adverse global and domestic factors, says an Ernst & Young report.
Abbott Nutrition is adopting a different tack in nutrition
Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.
Piramal Healthcare is in talk to buy US based healthcare company called Cambridge Major Labs for USD 200 million, reports Business Line.
Piramal Healthcare Ltd today said it has completed acquisition of the US-based Decision Resources Group (DRG) for USD 635 million (nearly Rs 3,400 crore).
When most pharmas are shying away from high-risk drug discovery, Piramal Healthcare is going for it full steam. Has it found a new way?
Drug firm Piramal Healthcare today said its director Swati Piramal has been elected as a member of the Harvard board of overseers. The board of overseers is over 350 years old and has 30 members, who are selected by the Harvard School graduates.
Piramal Healthcare today said it has decided to enter into the healthcare information management space by acquiring the US-based firm, Decision Resources Group(DRG) for a consideration of nearly USD 635 million (Rs 3,400 crore), reports CNBC TV18‘s Archana Shukla.
Drugmaker Piramal Healthcare has agreed to buy a US-based healthcare data provider for USD 635 million to boost research and development.
Mumbai-based Piramal Healthcare has agreed to acquire Decision Resources Group, a US-based company in the healthcare information segment for about Rs 3,400 crore.
Piramal Healthcare has reported a sales turnover of Rs 378.20 crore and a net loss of Rs 59.43 crore for the quarter ended Mar '12
Drugmaker Piramal Healthcare sees revenue potential of USD 1.5 billion from its newly acquired florbetaben molecule, which could be used to treat Alzheimer's disease, its chairman, Ajay Piramal, said on Monday.